Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
AstraZeneca
Moodys
McKinsey

Last Updated: August 19, 2022

Investigational Drug Information for Napabucasin


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Napabucasin?

Napabucasin is an investigational drug.

There have been 20 clinical trials for Napabucasin. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Boston Biomedical, Inc, Sumitomo Dainippon Pharma Oncology, Inc, and 1Globe Biomedical Co., Ltd.

There are thirty-nine US patents protecting this investigational drug and five hundred and thirty-eight international patents.

Recent Clinical Trials for Napabucasin
TitleSponsorPhase
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsBoston Biomedical, IncPhase 1
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsSumitomo Dainippon Pharma Oncology, IncPhase 1
A Study of Napabucasin in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer1Globe Biomedical Co., Ltd.Phase 3

See all Napabucasin clinical trials

Clinical Trial Summary for Napabucasin

Top disease conditions for Napabucasin
Top clinical trial sponsors for Napabucasin

See all Napabucasin clinical trials

US Patents for Napabucasin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Napabucasin See Plans and Pricing Anticancer agent Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP) See Plans and Pricing
Napabucasin See Plans and Pricing 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof Boston Biomedical, Inc. (Cambridge, MA) See Plans and Pricing
Napabucasin See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Napabucasin See Plans and Pricing Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer BOSTON BIOMEDICAL, INC. (Cambridge, MA) SUMITOMO DAINIPPON PHARMA CO., LTD. (Osaka-shi, Osaka, JP) See Plans and Pricing
Napabucasin See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Napabucasin See Plans and Pricing Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) See Plans and Pricing
Napabucasin See Plans and Pricing Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione SUMITOMO DAINIPPON PHARMA CO., LTD. (Osaka, JP) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Napabucasin

Drugname Country Document Number Estimated Expiration Related US Patent
Napabucasin Australia AU2015272560 2034-06-09 See Plans and Pricing
Napabucasin Canada CA2951627 2034-06-09 See Plans and Pricing
Napabucasin Denmark DK3153508 2034-06-09 See Plans and Pricing
Napabucasin European Patent Office EP3153508 2034-06-09 See Plans and Pricing
Napabucasin Spain ES2792851 2034-06-09 See Plans and Pricing
Napabucasin Japan JP2019206529 2034-06-09 See Plans and Pricing
Napabucasin Japan JP2022008894 2034-06-09 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
AstraZeneca
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.